申请人:Boehringer Ingelheim Pharmaceuticals Inc.
公开号:US20040063679A1
公开(公告)日:2004-04-01
Disclosed are novel cathepsin S, K, F, L and B reversible inhibitory compounds of the formulas (Ia) and (Ib) where R
1
, R
2
, R
3
, R
4
, R
5
, R
6
, R
8
, R
9
and X are defined herein. The compounds are useful for treating autoimmune and other diseases. Also disclosed are processes for making such novel compounds.
1
本发明涉及一种新的cathepsin S、K、F、L和B可逆抑制化合物,其化学式为(Ia)和(Ib),其中R1、R2、R3、R4、R5、R6、R8、R9和X的定义如下。该化合物可用于治疗自身免疫和其他疾病。同时,本发明还公开了制备这种新化合物的方法。